Pharma's Almanac | Viral Vector

45 Articles Available

0 2

Cell and Gene Therapy Regulatory

Navigating Regulatory Complexity for Cell and Gene Therapies

Viral Vectors

A Viral Vector CDMO Vision that Resonates

PAO-03-24-CL-06

Plasmid Manufacturing

Optimizing Plasmid Production to Meet Growing Demand

PAO-04-23-NI-01

Viral Vector Manufacturing

Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control

PAO-02-23-CL-03

Viral Vector Manufacturing

Optimizing Transient Transfection for Viral Vector Production

PAO-11-022-NI-09

Viral Vectors

Risk-Based Optimization of Viral Vector Processes Adds Real Value

PAO-09-022-CL-05

Cell and Gene Therapy

State of the Cell and Gene Therapy Market

PAO-10-022-NI-01

Cell and Gene Therapy Analytics

Accelerating the Development of High-Quality Cell and Gene Therapies with Comprehensive, In-house Analytical Support

PAO-06-022-CL-07

Viral Vector Manufacturing

Avid Bioservices, Inc. and CRB Highlight Efforts that Enabled Opening of First Phase of New Viral Vector Facility in California in Only Eight Months

PR-M06-22-05

New Facility

AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus

PR-M05-22-13

Viral Vector Manufacturing

Approaching Viral Vector Manufacturing With an Emphasis on Quality and Design

PAO-05-022-CL-02

Gene Therapy Analytics

Overcoming Analytical Challenges for Gene Therapies

PAO-02-022-CL-14

Viral Vector Manufacturing

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

PAO-02-022-CL-01

Vaccines

100 Years in Vaccines and Looking Toward the Future

PAO-01-22-R250-13

2021 Roundup: The Year of Cell and Gene Therapy

Viral Vaccines

Viral Vectors, Vaccines — A New Era Of Collaborative Design

PAO-10-21-CL-17

Cell and Gene Therapy

Coping with a Talent Shortage and Talent War in Cell and Gene Therapy

PAO-10-21-CL-12

Gene Therapy

A Customer-Centric Approach to Cell and Gene Therapy Manufacturing

PAO-10-21-CL-06

Viral Vectors

Navigating Analytical Requirements for GMP Viral Vectors

PAO-10-21-CL-02

Gene Therapy

Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing

PAO-10-21-CL-01

Gene Therapy

Pandemic Playbook for Gene Therapy Manufacturing

PAO-09-21-CL-14

Gene Therapy

Andelyn Biosciences: A New CDMO with Roots in Gene Therapy Research Set to Drive Key Manufacturing Advances

Cell and Gene Therapy

6 Analytical Strategies to Consider Before Submitting Your Cell and Gene Therapy Application

PAO-06-21-CL-04

Capacity Expansion

MilliporeSigma Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity with $110 Million Facility

PR-M04-20-NI-032

0 2

Viral Vector

45 Articles Available

Can't find what you're looking for? Try our advanced search.

Cell and Gene Therapy Regulatory

Navigating Regulatory Complexity for Cell and Gene Therapies

Viral Vectors

A Viral Vector CDMO Vision that Resonates

Plasmid Manufacturing

Optimizing Plasmid Production to Meet Growing Demand

Viral Vector Manufacturing

Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control

Viral Vector Manufacturing

Optimizing Transient Transfection for Viral Vector Production

Viral Vectors

Risk-Based Optimization of Viral Vector Processes Adds Real Value

Cell and Gene Therapy

State of the Cell and Gene Therapy Market

Cell and Gene Therapy Analytics

Accelerating the Development of High-Quality Cell and Gene Therapies with Comprehensive, In-house Analytical Support

Viral Vector Manufacturing

Avid Bioservices, Inc. and CRB Highlight Efforts that Enabled Opening of First Phase of New Viral Vector Facility in California in Only Eight Months

New Facility

AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus

Viral Vector Manufacturing

Approaching Viral Vector Manufacturing With an Emphasis on Quality and Design

Gene Therapy Analytics

Overcoming Analytical Challenges for Gene Therapies

Viral Vector Manufacturing

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

Vaccines

100 Years in Vaccines and Looking Toward the Future

2021 Roundup: The Year of Cell and Gene Therapy

Viral Vaccines

Viral Vectors, Vaccines — A New Era Of Collaborative Design

Cell and Gene Therapy

Coping with a Talent Shortage and Talent War in Cell and Gene Therapy

Gene Therapy

A Customer-Centric Approach to Cell and Gene Therapy Manufacturing

Viral Vectors

Navigating Analytical Requirements for GMP Viral Vectors

Gene Therapy

Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing

Gene Therapy

Pandemic Playbook for Gene Therapy Manufacturing

Gene Therapy

Andelyn Biosciences: A New CDMO with Roots in Gene Therapy Research Set to Drive Key Manufacturing Advances

Cell and Gene Therapy

6 Analytical Strategies to Consider Before Submitting Your Cell and Gene Therapy Application

Capacity Expansion

MilliporeSigma Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity with $110 Million Facility